Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 7/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | FLT1 | P17948 | 2/20 | 0.44 |
| ▸ | FLT4 | P35916 | 2/20 | 0.44 |
| ▸ | KDR | P35968 | 2/20 | 0.44 |
| ▸ | AKR1A1 | P14550 | 2/20 | 0.44 |
| ▸ | PRNP | P04156 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.42 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.42 |
| ▸ | ABL1 | P00519 | 1/20 | 0.42 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.42 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10487915 | 0.91 | AKR1B1 (0.57) | AKR1B1KMT2AALDH1A1AKR1A1MAPT | |
| SCHEMBL10487973 | 0.88 | AKR1B1 (0.57) | AKR1B1KMT2AAKR1A1P2RX7DGAT1 | |
| SCHEMBL5464898 | 0.86 | AKR1B1 (0.67) | AKR1B1KMT2ANPC1ALDH1A1LMNA | |
| SCHEMBL10487901 | 0.85 | AKR1B1 (0.52) | AKR1B1KMT2AALDH1A1AKR1A1MAPT | |
| SCHEMBL10487969 | 0.84 | AKR1B1 (0.64) | AKR1B1KMT2AALDH1A1AKR1A1MAPT | |
| SCHEMBL10487827 | 0.83 | AKR1B1 (0.50) | AKR1B1KMT2AALDH1A1LMNAAKR1A1 | |
| SCHEMBL10487825 | 0.83 | AKR1B1 (0.52) | AKR1B1KMT2AALDH1A1AKR1A1P2RX7 | |
| SCHEMBL10487794 | 0.81 | HPGD (0.62) | AKR1B1KMT2ANPC1ALDH1A1LMNA | |
| SCHEMBL17241555 | 0.81 | AKR1B1 (0.62) | AKR1B1KMT2AALDH1A1LMNAGAA | |
| SCHEMBL5466266 | 0.80 | AKR1B1 (1.00) | AKR1B1KMT2ANPC1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170137387-A1 | PHARMACOLOGICALLY ACTIVE QUINAZOLINEDIONE DERIVATIVES | ORION CORPORATION (FI) | 2017-05-18 | — | — | US | disclosed |
| EP-3140301-A1 | PHARMACOLOGICALLY ACTIVE QUINAZOLINEDIONE DERIVATIVES | Orion Corporation (FI) | 2017-03-15 | — | — | EP | disclosed |
| CN-106414430-A | Pharmacologically active quinazolinedione derivatives | 奥赖恩公司 | 2017-02-15 | — | — | CN | disclosed |
| WO-2015169999-A1 | PHARMACOLOGICALLY ACTIVE QUINAZOLINEDIONE DERIVATIVES | ORION CORPORATION (FI) | 2015-11-12 | — | — | WO | disclosed |
| EP-0712849-B1 | Process of preparation of substituted quinazolin-2,4-diones | CLARIANT GMBH (DE) | 2001-01-17 | — | — | EP | disclosed |
| EP-0712849-A2 | Process of preparation of substituted quinazolin-2,4-diones | HOECHST AKTIENGESELLSCHAFT (DE) | 1996-05-22 | — | — | EP | disclosed |
| CN-1017242-B | NEW QUIANZOLINE DERIVATIVES AND PROCESS FOR THEIR PRODUCTION | FUJISAWA PHARMACEUTICAL CO (JP) | 1992-07-01 | — | — | CN | disclosed |
| US-4883800-A | DIABETES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1989-11-28 | — | — | US | disclosed |
| US-4734419-A | Quinazoline derivatives, compositions thereof and their use in treating diabetic complications | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1988-03-29 | — | — | US | disclosed |
| CN-86106984-A | New quinazoline derivant and preparation method thereof | — | 1987-05-20 | — | — | CN | disclosed |
| EP-0218999-A2 | New quinazoline derivatives, process for their production and pharmaceutical compositions comprising them | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1987-04-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170137387-A1 | PHARMACOLOGICALLY ACTIVE QUINAZOLINEDIONE DERIVATIVES | GABRB1, GABRB3, GABRB2 | AKR1B1 1525/4885KMT2A 2358/4885NPC1 1329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.